Accessibility Menu
Braxia Scientific logo

Braxia Scientific(OTC) BRAXF

Market Cap$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Braxia Scientific last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-17
Braxia Scientific stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-07
1 month+0%USD 0.002026-07-16
3 month+0%USD 0.002026-05-19
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-06
3 year-99.99%USD 0.012023-08-18
5 year-100%USD 0.232021-08-18
Since inception-100%USD 0.702020-05-01

Braxia Scientific Financials at a Glance

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$2.21M

Net Income (TTM)

-CA$9.64M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-61.99 (Low)

Price

$0.00

Volume

969

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 17, 2025

BRAXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Braxia Scientific

Braxia Scientific Corp. is a biotechnology company focused on medical research and the provision of innovative ketamine therapies for individuals suffering from depression and related conditions. The company operates clinics and is engaged in the development of novel pharmaceutical compounds, including derivatives of ketamine and psilocybin.

Products and Services
  • Ketamine therapy for mental health disorders
  • Research and development of psychedelic compounds
  • Multidisciplinary clinics for comprehensive mental health treatment
Growth Outlook
  • Increasing demand for mental health treatments drives potential revenue growth
  • Expansion of clinic locations enhances service accessibility
  • Innovative research may lead to new therapeutic products
Financial Highlights
  • Recent quarterly revenue of CAD 492,445 shows a slight increase
  • Trailing twelve months (TTM) revenue of CAD 2,207,731 indicates growth potential
  • Current ratio of 1.00 suggests adequate short-term financial stability
Braxia Scientific Corp. operates in a rapidly evolving sector, addressing the growing need for effective mental health treatments. The company's focus on ketamine and psychedelic therapies positions it well within the biotechnology industry. Recent financial data indicates a modest increase in revenue, reflecting the company's ongoing efforts to expand its services and reach. The current ratio suggests that Braxia maintains a balanced approach to managing its short-term liabilities, which is crucial for sustaining operations and supporting growth initiatives. As the demand for innovative mental health solutions continues to rise, Braxia Scientific Corp. is strategically positioned to capitalize on emerging opportunities in the market.
AI Generated • Aug 15, 2026

Industry

Healthcare Providers and Services

CEO

Roger S. McIntyre, MD

Headquarters

Toronto, ON M5G 1Z6, CA

BRAXF Financials

Key Financial Metrics (TTM)

Gross Margin

9.12%

Operating Margin

-397.00%

Net Income Margin

-697.48%

Return on Equity

-248.72%

Return on Capital

-412.84%

Return on Assets

-338.34%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

283.28M

Volume

969

Avg. Volume

11.15K

Financials (TTM)

Gross Profit

-CA$1.05M

Operating Income

-CA$4.32M

EBITDA

-CA$3.85M

Operating Cash Flow

-CA$2.56M

Capital Expenditure

-CA$42.65K

Free Cash Flow

-CA$2.60M

Cash & ST Invst.

CA$128.34K

Total Debt

CA$636.64K

Braxia Scientific Performance Analysis

Braxia Scientific annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31CAD 1,186,038N/A
20232023-03-31CAD 1,424,29120.1%
Braxia Scientific sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-03-316.8%
Q12023-06-3014.9%
Q22023-09-30-1.0%
Q32023-12-31-17.1%
Braxia Scientific annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31CAD -0.06N/A
20232023-03-31CAD -0.04-21.2%
Braxia Scientific sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-03-31-222.2%
Q12023-06-3089.7%
Q22023-09-3066.7%
Q32023-12-31-240.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

CA$492.45K

+0.7%

Gross Profit

CA$81.98K

+108.7%

Gross Margin

16.65%

N/A

Market Cap

$300.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$60.00

N/A

Employees

5

N/A

Net Income

-CA$907.05K

+58.2%

EBITDA

-CA$807.51K

+63.8%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

CA$128.34K

-91.4%

Total Debt

CA$636.64K

+305.0%

Accounts Receivable

CA$91.03K

-58.0%

Inventory

CA$0.00

-100.0%

Long Term Debt

CA$501.04K

+270.5%

Short Term Debt

CA$135.60K

+74.5%

Return on Assets

-3.38%

N/A

Return on Invested Capital

-4.31%

N/A

Free Cash Flow

-CA$541.68K

+85.1%

Operating Cash Flow

-CA$532.56K

+85.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PBLAPanbela Therapeutics, Inc.
$0.00+9900.00%
AVXTAVAX Technologies, Inc.
$0.00+0.00%
ARYCArrayit Corporation
$0.00+0.00%
DNAGDNAPrint Genomics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.25-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About BRAXF

What is the current price of Braxia Scientific?

Braxia Scientific is trading at $0.00 per share.

What is the 52-week range for Braxia Scientific?

Over the past 52 weeks, Braxia Scientific has traded between $0.00 and $0.00.

How much debt does Braxia Scientific have?

As of the most recent reporting period, Braxia Scientific reported total debt of CA$112.21K.

How much cash does Braxia Scientific have on hand?

Braxia Scientific reported CA$1.08M in cash and cash equivalents in its most recent financial results.

What is Braxia Scientific’s dividend yield?

Braxia Scientific does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.